MedPath

Effect of Vitamin B12 oral spray

Not Applicable
Registration Number
CTRI/2023/06/054348
Lead Sponsor
Dr Nusrat Nabi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

•Strictly vegetarian patients

•Vitamin B12 deficiency; svB12 <200 pg/mL (148 pmol/L)

•Ability to understand and give informed consent

Exclusion Criteria

1.Oral submucosal fibrosis

2.Oral leukoplakia

3.Pregnant or breastfeeding

4.Prior treatment with Vitamin B12 supplementation (last 1 month)

5.Any other medical condition that would make participation in the study unsafe or unlikely to yield valid results

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
will comprise of the percentage of patients achieving svB12 levels 200 pg/mL (148 pmol/L), 20% increase and 50pg/mL increase, at 3 and 6 weeks of treatment with Vitamin B12 oral spray as well as the incidence of adverse events experienced during the treatment period.Timepoint: 3weeks&6weeks
Secondary Outcome Measures
NameTimeMethod
will include serum Vitamin B12 levels, hemoglobin, hematocrit, and red blood cell count and MCV at baseline, 3 weeks and 6 weeks of treatmentTimepoint: 3weeks&6weeks
© Copyright 2025. All Rights Reserved by MedPath